SAN DIEGO--(

圣地亚哥--(

BUSINESS WIRE

商业热线

)--Iambic Therapeutics, a clinical-stage biotechnology company developing novel medicines using its AI-driven discovery and development platform, announced that Michael Secora, Ph.D. will be its Chief Corporate Development Officer and Chief Financial Officer. Dr Secora will lead Iambic's finance and corporate development activities, helping frame its growing pipeline and industry-leading platform to potential partners, investors, and other stakeholders..

)--Iambic Therapeutics是一家临床阶段的生物技术公司，利用其人工智能驱动的发现和开发平台开发新药，宣布迈克尔·塞科拉博士将担任其首席企业开发官和首席财务官。塞科拉博士将领导Iambic的财务和企业发展活动，帮助其为潜在合作伙伴、投资者和其他利益相关者构建不断增长的渠道和行业领先的平台。。

“Michael is a unique and effective leader with experience as a scientist, investor, and operator. He has demonstrated strategic and tactical success leading both scientific and technical teams as well as business-related and capital raising efforts,” said Tom Miller, Ph.D., Co-Founder and CEO of Iambic.

Iambic联合创始人兼首席执行官汤姆·米勒（TomMiller）博士表示：“迈克尔是一位独特而有效的领导者，拥有科学家、投资者和运营商的经验。他在领导科学和技术团队以及商业相关和融资方面取得了战略和战术上的成功。”。

“More importantly, Michael is passionate about the increased inclusion of technology within the life sciences to transform drug discovery and development. We are excited to welcome Michael to Iambic and look forward to driving our scientific and business objectives forward together.'.

“更重要的是，迈克尔热衷于将技术更多地纳入生命科学，以改变药物的发现和开发。我们很高兴欢迎迈克尔加入Iambic，并期待着共同推动我们的科学和商业目标。”。

For over a decade, Dr. Secora has been a leader in defining the value proposition for technology-driven drug development, drawing on his scientific, capital markets and business expertise. At Recursion (NASDAQ: RXRX), he led finance, communications, and investor relations activities as well as corporate strategy for translating value both internally and externally across Recursion's internal pipeline, external partnerships, and data.

十多年来，塞科拉博士凭借其科学、资本市场和商业专业知识，在确定技术驱动药物开发的价值主张方面一直处于领先地位。在Recursion（纳斯达克股票代码：RXRX），他领导财务、通信和投资者关系活动，以及通过Recursion的内部渠道、外部合作伙伴关系和数据在内部和外部转化价值的公司战略。

Dr. Secora led efforts related to Recursion's entering collaborations with Bayer, Roche-Genentech, NVIDIA, Google, Tempus, and others; combining with Exscientia (EXAI), Cyclica, Valence, and Vium; and raising over $1.3 billion for Recursion across both private and public fundraising rounds..

塞科拉博士领导了Recursion与拜耳、罗氏基因泰克、NVIDIA、谷歌、Tempus等公司的合作；结合Exscientia（EXAI），Cyclica，Valence和Vium；并筹集了超过13亿美元的资金，用于私人和公共筹款循环。。

'There are many things that I am excited about at Iambic. First, committed leadership - I admire how Tom and Fred left their professorships at Caltech and Bristol to found and lead Iambic. Second, experimental platform - I am impressed with the integration and automation of chemical synthesis, mass spectrometry, target and pathway deconvolution, and data flow optimization.

。首先，坚定的领导力——我很钦佩汤姆和弗雷德如何离开加州理工学院和布里斯托尔的教授职位，创立并领导Iambic。第二，实验平台-化学合成，质谱，目标和途径反卷积以及数据流优化的集成和自动化给我留下了深刻的印象。

Third, AI-technology - I believe that Iambic's expertise in active learning and multimodal transformer models has created industry-leading computational tools. Lastly, clinical pipeline advancement - Iambic has demonstrated an ability to go from beginning a program to a Phase 1 clinical trial in approximately 2 years, which is extraordinarily fast,' said Dr.

第三，人工智能技术-我相信Iambic在主动学习和多模式变压器模型方面的专业知识创造了业界领先的计算工具。最后，临床管道进展-Iambic已经证明能够在大约2年内从一个项目开始进入第一阶段临床试验，这是非常快的，”博士说。

Secora..

塞科拉。。

Iambic’s pipeline includes IAM1363, a potential best-in-class, highly selective and brain penetrant small molecule inhibitor of both wild-type and oncogenic HER2 mutants currently in a Phase 1 study with data anticipated in 2025, as well as a potential first-in-class selective dual CDK2/4 inhibitor for multiple cancer indications, an allosteric inhibitor for KIF18A, and additional new programs..

Iambic的管道包括IAM1363，一种潜在的同类最佳，高选择性和脑渗透性的野生型和致癌HER2突变体小分子抑制剂，目前正在进行一期研究，预计2025年的数据，以及潜在的一流选择性双重CDK2/4抑制剂，用于多种癌症适应症，KIF18A的变构抑制剂和其他新程序。。

Dr. Secora went on to say, “I have been impressed with Iambic's development over the last few years as well as the strength of Iambic's board, scientific advisors, and partners. As a scientist and investor, I believe in the increasing inclusion of technology into many aspects of our way of life. As a leader, I choose to serve organizations that have the potential for substantial and long-term positive impact.

塞科拉博士接着说：“Iambic在过去几年的发展以及Iambic董事会、科学顾问和合作伙伴的实力给我留下了深刻的印象。作为一名科学家和投资者，我相信技术越来越多地融入我们生活方式的方面。作为领导者，我选择为那些有潜力产生重大和长期积极影响的组织服务。

I see Iambic having such an impact in the life science and technology industries now and into the future.'.

我看到Iambic在现在和未来的生命科学和技术行业都产生了如此大的影响。”。

Prior to Recursion, Dr. Secora had a successful 10-year investing career at Laurion Capital as Managing Director and Head of Capital Markets and Venture, where he focused on emerging technologies and the life sciences and was an early advocate and investor in the TechBio space. Dr. Secora is an alumnus of Princeton University with a doctorate in Applied and Computational Mathematics and has undergraduate degrees in Mathematics and Physics and minor degrees in Astronomy and Writing and Humanistic Studies from the Massachusetts Institute of Technology (MIT)..

在Recursion之前，Secora博士在Laurion Capital拥有成功的10年投资生涯，担任董事总经理兼资本市场和风险投资主管，专注于新兴技术和生命科学，是TechBio领域的早期倡导者和投资者。塞科拉博士是普林斯顿大学（Princeton University）的校友，拥有应用数学和计算数学博士学位，拥有麻省理工学院（MIT）的数学和物理本科学位以及天文学、写作和人文研究的副学士学位。。

About Iambic’s AI-Driven Discovery Platform

关于Iambic的人工智能驱动的发现平台

The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures.

Iambic AI驱动的平台是为了解决药物发现中最具挑战性的设计问题而创建的，它利用了技术创新，例如Enchant，一种预测发现早期临床结果的多模式变压器模型，以及NeuralPLexer，蛋白质和蛋白质配体结构的最佳预测因子。

The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates.

将物理原理集成到平台的AI架构中可以提高数据效率，并允许分子模型在可能的化学结构空间中广泛冒险。该平台能够识别用于参与难以解决的生物靶标的新型化学模式，发现优化治疗窗口的定义产品概况，以及针对高度分化的候选开发进行多参数优化。

Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence..

通过将人工智能生成的分子设计与自动实验执行紧密结合，Iambic以每周的节奏完成设计-制作-测试周期。。

About Iambic Therapeutics

关于抑扬格疗法

Founded in 2019 and headquartered in San Diego, California, Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics.

Iambic Therapeutics成立于2019年，总部位于加利福尼亚州圣地亚哥，凭借其独特的人工智能驱动的药物发现平台，正在颠覆治疗学的格局。。

The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to the clinical stage with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs.

Iambic平台已被证明可以以前所未有的速度，跨越多个目标类别和作用机制，为临床阶段提供高质量，差异化的治疗方法。Iambic团队正在推进临床资产的内部管道，以解决紧急未满足的患者需求。

Learn more about the Iambic team, platform, and pipeline at .

了解有关Iambic团队、平台和管道的更多信息。

iambic.ai

iambic.ai